MoneyAM MoneyAM
 Home   Log In   Register   Our Services   My Account   Contact   Help 
 Stockwatch   Level 2   Portfolio   Charts   Research   Share Price   Awards   Indices   Market Scan   Company Zone   Traders' Room 
 Funds   Trades   Terminal   Alerts   Heatmaps   News   Stock Screener   Forward Diary   Forex Prices   Director Deals   Investors' Room 
 CFDs   Shares   SIPPs   ISAs   Forex   ETFs   Videos   Comparison Tables   Spread Betting   Broker Notes   Shares Magazine 
You are NOT currently logged in

 
Filter Criteria  
Epic: Keywords: 
From: Time:  (hh:mm) RNS:  MonAM: 
To: Time:  (hh:mm)
Please Note - Streaming News is only available to subscribers to the Active Level and above
 


Byotrol shares up as wins patent for novel anti-viral seaweed extract

ALN

Byotrol PLC shares jumped on Thursday, after it said it has won a UK patent for novel anti-viral seaweed extract.

Shares in the Chester, England-based developer of antimicrobial technologies and products were up 9.7% to 2.08 pence each in London on Thursday morning. Over the last twelve months, the stock is down 18%.

Byotrol said it has received approval for a UK patent, following ‘its discovery of unique anti-viral properties of certain enhanced extracts of commonly available brown seaweed.’

It noted that the grant of the patent application gives the company validated, valuable and protected intellectual property, to support the development of commercial relationships.

In the UK and Europe, seaweed extracts are not as yet approved as active materials for biocidal products. Therefore, Byortol said it is now actively exploring alternative applications in very sizeable markets such as over-the-counter products for the prophylactic treatment of viral conditions including colds, flu, coronaviruses and cold sores.

Chair Trevor Francis said: ‘We are delighted to have secured the first patent for our seaweed-based anti-viral technologies. It is another good indication of the quality of our technical capability, and it will most certainly help us as we intensify the search for commercial partners. It also adds to our already significant level of intellectual property in antimicrobials.’

Copyright 2023 Alliance News Ltd. All Rights Reserved.